{
    "clinical_study": {
        "@rank": "125954", 
        "acronym": "SPACE", 
        "arm_group": {
            "arm_group_label": "Non-Small Cell Lung Cancer", 
            "description": "Locally advanced stage IIIB or IV (metastatic) or Relapsed Non-Small Cell Lung Cancer"
        }, 
        "biospec_descr": {
            "textblock": "DNA from lung cancer tumor tissue obtained by bronchoscopy, needle biopsy or surgical\n      resection"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Using DNA acquired from tumor tissue, sequencing and PNA-clamping for EGFR gene will be\n      performed. The detection rates of EGFR mutation will be compared using paired samples."
        }, 
        "brief_title": "Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Single arm, open label, prospective, observational study of gefitinib treatment for locally\n      advanced (stage IIIB) or IV (metastatic) or relapsed NSCLC patients.\n\n      Using DNA acquired from tumor tissue, sequencing and PNA-clamping for EGFR gene will be\n      performed. The detection rates of EGFR mutation will be compared using paired samples."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Locally advanced stage IIIB not suitable for curative therapy or stage IV\n             (metastatic) disease or relapsed NSCLC\n\n          -  ECOG Performance status 0~2.\n\n          -  Written Informed Consent\n\n          -  Female or male patients aged 18 years or over, eligible for treatment for NSCLC\n\n        Exclusion Criteria:\n\n          -  Previous exposure to EGFR-TKI\n\n          -  Concomitant use of other anti-cancer drugs with EGFR-TKI\n\n          -  Patients without available Tumor DNA\n\n          -  As judged by the investigator, any evidence of severe or uncontrolled systemic\n             disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal\n             disease)\n\n          -  Evidence of any other significant clinical disorder or laboratory finding that makes\n             it undesirable for the subject to participate in the study\n\n          -  Pregnancy or breast-feeding women (women of child\u00acbearing potential). Women of\n             childbearing potential must practice acceptable methods of birth control to prevent\n             pregnancy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Locally advanced stage IIIB or IV (metastatic) or Relapsed Non-Small Cell Lung Cancer"
            }
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01767974", 
            "org_study_id": "ISSIRES0066"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Non-Small Cell lung cancer", 
        "lastchanged_date": "January 11, 2013", 
        "location": {
            "contact": {
                "email": "kyc0923@jnu.ac.kr", 
                "last_name": "Young-Chul Kim, MD, PhD", 
                "phone": "82-61-379-7614"
            }, 
            "contact_backup": {
                "email": "hhw55@naver.com", 
                "last_name": "Ju-Mi Yoon, MS", 
                "phone": "82-61-379-7861"
            }, 
            "facility": {
                "address": {
                    "city": "Hwasun-Gun", 
                    "country": "Korea, Republic of", 
                    "state": "Jeonnam", 
                    "zip": "519-763"
                }, 
                "name": "Chonnam National University Hwasun Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Kyu-Sik Kim, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "In-Jae Oh, MD, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer", 
        "overall_contact": {
            "email": "kyc0923@jnu.ac.kr", 
            "last_name": "Young-Chul Kim, MD, PhD", 
            "phone": "82-61-379-7614"
        }, 
        "overall_contact_backup": {
            "email": "hhw55@naver.com", 
            "last_name": "Ju-Mi Yoon, MS", 
            "phone": "82-61-379-7861"
        }, 
        "overall_official": {
            "affiliation": "Chonnam National University Hospital", 
            "last_name": "Young-Chul Kim, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To prove higher detection rate of EGFR mutation with PNA clamping compared with sequencing", 
            "measure": "Detection rate of EGFR mutation", 
            "safety_issue": "No", 
            "time_frame": "two weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01767974"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chonnam National University Hospital", 
            "investigator_full_name": "Young-Chul Kim", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To analyze the Sequencing negative/PNA clamping positive group (where sample is available) with another sensitive technique COBAS test", 
            "measure": "Verification of PNA positive casese", 
            "safety_issue": "No", 
            "time_frame": "Two weeks"
        }, 
        "source": "Chonnam National University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Chonnam National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2013"
    }
}